Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-11-01

AUTHORS

Tomoko Horinouchi, Mayumi Sako, Koichi Nakanishi, Kenji Ishikura, Shuichi Ito, Hidefumi Nakamura, Mari Saito Oba, Kandai Nozu, Kazumoto Iijima

ABSTRACT

BackgroundIdiopathic nephrotic syndrome (INS) is the most common chronic glomerular disease in children. Approximately 80–90% of patients with childhood INS have steroid-sensitive nephrotic syndrome (SSNS), and can obtain remission with steroid therapy, while the remainder have steroid-resistant nephrotic syndrome (SRNS). Furthermore, approximately 50% of children with SSNS develop frequently-relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS). Children with FRNS/SDNS are usually treated with immunosuppressive agents such as cyclosporine, cyclophosphamide, or mizoribine in Japan. However, 10–20% of children receiving immunosuppressive agents still show frequent relapse and/or steroid dependence during or after treatment, which is defined as complicated FRNS/SDNS. Furthermore, 30% of SRNS patients who obtain remission after additional treatments such as cyclosporine also turn out to be complicated FRNS/SDNS. For such complicated FRNS/SDNS patients, rituximab (RTX) is currently used; however, recurrence after RTX treatment also remains an open issue. Because long-term use of existing immunosuppressive drugs has limitations, development of a novel treatment for maintenance therapy after RTX is desirable. Mycophenolate mofetil (MMF) is an immunosuppressive drug with fewer side effects than cyclosporine or cyclophosphamide. Importantly, recent studies have reported the efficacy of MMF in children with nephrotic syndrome.MethodsWe conduct a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of MMF after RTX therapy in children with complicated FRNS/SDNS. Patients are allocated to either RTX plus MMF treatment group, or RTX plus placebo treatment group. For the former group, MMF is administered at a dose of 1000–1200 mg/m2/day (maximum 2 g/day) twice daily for 17 months after RTX treatment. The primary endpoint is time-to-treatment failure (development of frequent relapses, steroid dependence or steroid resistance).DiscussionThe results will provide important data on the use of MMF as maintenance therapy after RTX to prevent complicated FRNS/SDNS patients from declining into treatment failure. In future, MMF in conjunction with RTX treatment may permit increased duration of remission in ‘complicated’ FRNS/SDNS cases.Trial registrationThis trial was prospectively registered to UMIN Clinical Trials Registry on June 23, 2014 (UMIN Trial ID: UMIN000014347). More... »

PAGES

302

References to SciGraph publications

  • 2005-02-18. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children in PEDIATRIC NEPHROLOGY
  • 2007-10-16. Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome in PEDIATRIC NEPHROLOGY
  • 2011-05-10. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome in PEDIATRIC NEPHROLOGY
  • 2005-05-13. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome in PEDIATRIC NEPHROLOGY
  • 2006-11-04. A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome in PEDIATRIC NEPHROLOGY
  • 2004-04-08. Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy in PEDIATRIC NEPHROLOGY
  • 2010-01-05. Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine in PEDIATRIC NEPHROLOGY
  • 2006-03-29. Short-term outcomes of severe lupus nephritis in a cohort of predominantly African–American children in PEDIATRIC NEPHROLOGY
  • 2015-02-06. Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy in CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • 2016-07-15. Rituximab for nephrotic syndrome in children in CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • 1999-02. Two-year cyclosporin treatment in children with steroid-dependent nephrotic syndrome in PEDIATRIC NEPHROLOGY
  • 2016-09-02. High incidence of idiopathic nephrotic syndrome in East Asian children: a nationwide survey in Japan (JP-SHINE study) in CLINICAL AND EXPERIMENTAL NEPHROLOGY
  • 2003-05-28. Use of mycophenolate mofetil in steroid-dependent and -resistant nephrotic syndrome in PEDIATRIC NEPHROLOGY
  • 2003-11-25. Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil in PEDIATRIC NEPHROLOGY
  • 2013-01-13. Prospective 5-year follow-up of cyclosporine treatment in children with steroid-resistant nephrosis in PEDIATRIC NEPHROLOGY
  • 2009-07-01. Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children in PEDIATRIC NEPHROLOGY
  • 2011-05-01. Should we consider MMF therapy after rituximab for nephrotic syndrome? in PEDIATRIC NEPHROLOGY
  • 2008-08-01. Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases in PEDIATRIC NEPHROLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s12882-018-1099-7

    DOI

    http://dx.doi.org/10.1186/s12882-018-1099-7

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1107953414

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30382824


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Child", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Double-Blind Method", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Therapy, Combination", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Immunologic Factors", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mycophenolic Acid", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Nephrotic Syndrome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Recurrence", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rituximab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Steroids", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Treatment Outcome", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Pediatrics, Kobe University Graduate School of Medicine, 5-1 Kusunoki-cho 7 chome, Chuo-ku, 650-0017, Kobe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.31432.37", 
              "name": [
                "Department of Pediatrics, Kobe University Graduate School of Medicine, 5-1 Kusunoki-cho 7 chome, Chuo-ku, 650-0017, Kobe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Horinouchi", 
            "givenName": "Tomoko", 
            "id": "sg:person.013371647075.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013371647075.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division for Clinical Trials, Department of Clinical Research Promotion, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.63906.3a", 
              "name": [
                "Division for Clinical Trials, Department of Clinical Research Promotion, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sako", 
            "givenName": "Mayumi", 
            "id": "sg:person.01032464245.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032464245.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan", 
              "id": "http://www.grid.ac/institutes/grid.267625.2", 
              "name": [
                "Department of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nakanishi", 
            "givenName": "Koichi", 
            "id": "sg:person.0611445101.47", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611445101.47"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.63906.3a", 
              "name": [
                "Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ishikura", 
            "givenName": "Kenji", 
            "id": "sg:person.01112735663.13", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112735663.13"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan", 
              "id": "http://www.grid.ac/institutes/grid.268441.d", 
              "name": [
                "Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ito", 
            "givenName": "Shuichi", 
            "id": "sg:person.012302533312.63", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012302533312.63"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.63906.3a", 
              "name": [
                "Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nakamura", 
            "givenName": "Hidefumi", 
            "id": "sg:person.016521443562.02", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016521443562.02"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Medical Statistics, Toho University, Tokyo, Japan", 
              "id": "http://www.grid.ac/institutes/grid.265050.4", 
              "name": [
                "Department of Medical Statistics, Toho University, Tokyo, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Oba", 
            "givenName": "Mari Saito", 
            "id": "sg:person.0755444204.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755444204.45"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pediatrics, Kobe University Graduate School of Medicine, 5-1 Kusunoki-cho 7 chome, Chuo-ku, 650-0017, Kobe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.31432.37", 
              "name": [
                "Department of Pediatrics, Kobe University Graduate School of Medicine, 5-1 Kusunoki-cho 7 chome, Chuo-ku, 650-0017, Kobe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Nozu", 
            "givenName": "Kandai", 
            "id": "sg:person.0717317506.56", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717317506.56"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pediatrics, Kobe University Graduate School of Medicine, 5-1 Kusunoki-cho 7 chome, Chuo-ku, 650-0017, Kobe, Japan", 
              "id": "http://www.grid.ac/institutes/grid.31432.37", 
              "name": [
                "Department of Pediatrics, Kobe University Graduate School of Medicine, 5-1 Kusunoki-cho 7 chome, Chuo-ku, 650-0017, Kobe, Japan"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Iijima", 
            "givenName": "Kazumoto", 
            "id": "sg:person.01360637141.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360637141.54"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/s00467-006-0060-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039372955", 
              "https://doi.org/10.1007/s00467-006-0060-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-011-1886-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038755333", 
              "https://doi.org/10.1007/s00467-011-1886-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-003-1300-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032638307", 
              "https://doi.org/10.1007/s00467-003-1300-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-006-0294-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001089825", 
              "https://doi.org/10.1007/s00467-006-0294-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-008-0814-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047664910", 
              "https://doi.org/10.1007/s00467-008-0814-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-012-2393-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1020767792", 
              "https://doi.org/10.1007/s00467-012-2393-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-004-1778-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039990387", 
              "https://doi.org/10.1007/s00467-004-1778-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-011-1894-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032375811", 
              "https://doi.org/10.1007/s00467-011-1894-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-003-1175-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010530284", 
              "https://doi.org/10.1007/s00467-003-1175-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10157-016-1319-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022803771", 
              "https://doi.org/10.1007/s10157-016-1319-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-004-1434-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1034927167", 
              "https://doi.org/10.1007/s00467-004-1434-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-009-1377-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022984402", 
              "https://doi.org/10.1007/s00467-009-1377-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-005-1877-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025163770", 
              "https://doi.org/10.1007/s00467-005-1877-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10157-014-1030-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019458362", 
              "https://doi.org/10.1007/s10157-014-1030-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-009-1191-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052697168", 
              "https://doi.org/10.1007/s00467-009-1191-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10157-016-1313-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036768788", 
              "https://doi.org/10.1007/s10157-016-1313-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00467-007-0617-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004619628", 
              "https://doi.org/10.1007/s00467-007-0617-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s004670050558", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045165754", 
              "https://doi.org/10.1007/s004670050558"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2018-11-01", 
        "datePublishedReg": "2018-11-01", 
        "description": "BackgroundIdiopathic nephrotic syndrome (INS) is the most common chronic glomerular disease in children. Approximately 80\u201390% of patients with childhood INS have steroid-sensitive nephrotic syndrome (SSNS), and can obtain remission with steroid therapy, while the remainder have steroid-resistant nephrotic syndrome (SRNS). Furthermore, approximately 50% of children with SSNS develop frequently-relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS). Children with FRNS/SDNS are usually treated with immunosuppressive agents such as cyclosporine, cyclophosphamide, or mizoribine in Japan. However, 10\u201320% of children receiving immunosuppressive agents still show frequent relapse and/or steroid dependence during or after treatment, which is defined as complicated FRNS/SDNS. Furthermore, 30% of SRNS patients who obtain remission after additional treatments such as cyclosporine also turn out to be complicated FRNS/SDNS. For such complicated FRNS/SDNS patients, rituximab (RTX) is currently used; however, recurrence after RTX treatment also remains an open issue. Because long-term use of existing immunosuppressive drugs has limitations, development of a novel treatment for maintenance therapy after RTX is desirable. Mycophenolate mofetil (MMF) is an immunosuppressive drug with fewer side effects than cyclosporine or cyclophosphamide. Importantly, recent studies have reported the efficacy of MMF in children with nephrotic syndrome.MethodsWe conduct a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of MMF after RTX therapy in children with complicated FRNS/SDNS. Patients are allocated to either RTX plus MMF treatment group, or RTX plus placebo treatment group. For the former group, MMF is administered at a dose of 1000\u20131200\u00a0mg/m2/day (maximum 2\u00a0g/day) twice daily for 17\u00a0months after RTX treatment. The primary endpoint is time-to-treatment failure (development of frequent relapses, steroid dependence or steroid resistance).DiscussionThe results will provide important data on the use of MMF as maintenance therapy after RTX to prevent complicated FRNS/SDNS patients from declining into treatment failure. In future, MMF in conjunction with RTX treatment may permit increased duration of remission in \u2018complicated\u2019 FRNS/SDNS cases.Trial registrationThis trial was prospectively registered to UMIN Clinical Trials Registry on June 23, 2014 (UMIN Trial ID: UMIN000014347).", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s12882-018-1099-7", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.7853213", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1024626", 
            "issn": [
              "1471-2369"
            ], 
            "name": "BMC Nephrology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "19"
          }
        ], 
        "keywords": [
          "steroid-dependent nephrotic syndrome", 
          "steroid-sensitive nephrotic syndrome", 
          "steroid-resistant nephrotic syndrome", 
          "placebo-controlled trial", 
          "FRNS/", 
          "mycophenolate mofetil", 
          "nephrotic syndrome", 
          "maintenance therapy", 
          "RTX treatment", 
          "immunosuppressive agents", 
          "treatment failure", 
          "immunosuppressive drugs", 
          "treatment groups", 
          "common chronic glomerular disease", 
          "efficacy of MMF", 
          "safety of MMF", 
          "use of MMF", 
          "UMIN Clinical Trials Registry", 
          "BackgroundIdiopathic nephrotic syndrome", 
          "MMF treatment group", 
          "placebo treatment groups", 
          "duration of remission", 
          "Clinical Trials Registry", 
          "chronic glomerular disease", 
          "long-term use", 
          "steroid therapy", 
          "primary endpoint", 
          "rituximab treatment", 
          "frequent relapses", 
          "RTX therapy", 
          "SRNS patients", 
          "Trials Registry", 
          "steroid dependence", 
          "glomerular disease", 
          "side effects", 
          "novel treatments", 
          "patients", 
          "syndrome", 
          "therapy", 
          "remission", 
          "cyclosporine", 
          "m2/day", 
          "RTX", 
          "additional treatment", 
          "trials", 
          "former group", 
          "mofetil", 
          "multicenter", 
          "cyclophosphamide", 
          "treatment", 
          "children", 
          "drugs", 
          "efficacy", 
          "Recent studies", 
          "group", 
          "mizoribine", 
          "relapse", 
          "recurrence", 
          "failure", 
          "registry", 
          "agents", 
          "MethodsWe", 
          "disease", 
          "dose", 
          "endpoint", 
          "months", 
          "duration", 
          "days", 
          "safety", 
          "important data", 
          "use", 
          "remainder", 
          "cases", 
          "study", 
          "effect", 
          "data", 
          "development", 
          "time", 
          "Japan", 
          "conjunction", 
          "results", 
          "limitations", 
          "INS", 
          "future", 
          "issues", 
          "dependence", 
          "open issues"
        ], 
        "name": "Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07)", 
        "pagination": "302", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1107953414"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s12882-018-1099-7"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30382824"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s12882-018-1099-7", 
          "https://app.dimensions.ai/details/publication/pub.1107953414"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-05-10T10:21", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_783.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s12882-018-1099-7"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12882-018-1099-7'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12882-018-1099-7'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12882-018-1099-7'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12882-018-1099-7'


     

    This table displays all metadata directly associated to this object as RDF triples.

    338 TRIPLES      22 PREDICATES      142 URIs      116 LITERALS      18 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s12882-018-1099-7 schema:about N0e556e5a77d0414997b9a79cb17ddca1
    2 N290bf30513d64ac9bdeffc73ae445ac8
    3 N3b371baeea78457f97868356d1be7b06
    4 N3c4efa40fd724349a18a3e4984c97ced
    5 N65461cf9e5e94ee09aee68ba2b8de9df
    6 N664795cad18e454686d95897912a2177
    7 N6f94ed8c33744652b5a4d48a265d351b
    8 N79422b1e743742c5b263d5762ac9bbbf
    9 N92df3b3007a249fc9235a615c18ae6e4
    10 N9c9711aba86e4e849a41f1730927606d
    11 Nfecab5583147458d94a3a0b37cc07431
    12 anzsrc-for:11
    13 anzsrc-for:1103
    14 schema:author N1764a0759997421d895569a119aa8908
    15 schema:citation sg:pub.10.1007/s00467-003-1175-4
    16 sg:pub.10.1007/s00467-003-1300-4
    17 sg:pub.10.1007/s00467-004-1434-z
    18 sg:pub.10.1007/s00467-004-1778-4
    19 sg:pub.10.1007/s00467-005-1877-x
    20 sg:pub.10.1007/s00467-006-0060-3
    21 sg:pub.10.1007/s00467-006-0294-0
    22 sg:pub.10.1007/s00467-007-0617-9
    23 sg:pub.10.1007/s00467-008-0814-1
    24 sg:pub.10.1007/s00467-009-1191-0
    25 sg:pub.10.1007/s00467-009-1377-5
    26 sg:pub.10.1007/s00467-011-1886-x
    27 sg:pub.10.1007/s00467-011-1894-x
    28 sg:pub.10.1007/s00467-012-2393-4
    29 sg:pub.10.1007/s004670050558
    30 sg:pub.10.1007/s10157-014-1030-x
    31 sg:pub.10.1007/s10157-016-1313-5
    32 sg:pub.10.1007/s10157-016-1319-z
    33 schema:datePublished 2018-11-01
    34 schema:datePublishedReg 2018-11-01
    35 schema:description BackgroundIdiopathic nephrotic syndrome (INS) is the most common chronic glomerular disease in children. Approximately 80–90% of patients with childhood INS have steroid-sensitive nephrotic syndrome (SSNS), and can obtain remission with steroid therapy, while the remainder have steroid-resistant nephrotic syndrome (SRNS). Furthermore, approximately 50% of children with SSNS develop frequently-relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS). Children with FRNS/SDNS are usually treated with immunosuppressive agents such as cyclosporine, cyclophosphamide, or mizoribine in Japan. However, 10–20% of children receiving immunosuppressive agents still show frequent relapse and/or steroid dependence during or after treatment, which is defined as complicated FRNS/SDNS. Furthermore, 30% of SRNS patients who obtain remission after additional treatments such as cyclosporine also turn out to be complicated FRNS/SDNS. For such complicated FRNS/SDNS patients, rituximab (RTX) is currently used; however, recurrence after RTX treatment also remains an open issue. Because long-term use of existing immunosuppressive drugs has limitations, development of a novel treatment for maintenance therapy after RTX is desirable. Mycophenolate mofetil (MMF) is an immunosuppressive drug with fewer side effects than cyclosporine or cyclophosphamide. Importantly, recent studies have reported the efficacy of MMF in children with nephrotic syndrome.MethodsWe conduct a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of MMF after RTX therapy in children with complicated FRNS/SDNS. Patients are allocated to either RTX plus MMF treatment group, or RTX plus placebo treatment group. For the former group, MMF is administered at a dose of 1000–1200 mg/m2/day (maximum 2 g/day) twice daily for 17 months after RTX treatment. The primary endpoint is time-to-treatment failure (development of frequent relapses, steroid dependence or steroid resistance).DiscussionThe results will provide important data on the use of MMF as maintenance therapy after RTX to prevent complicated FRNS/SDNS patients from declining into treatment failure. In future, MMF in conjunction with RTX treatment may permit increased duration of remission in ‘complicated’ FRNS/SDNS cases.Trial registrationThis trial was prospectively registered to UMIN Clinical Trials Registry on June 23, 2014 (UMIN Trial ID: UMIN000014347).
    36 schema:genre article
    37 schema:inLanguage en
    38 schema:isAccessibleForFree true
    39 schema:isPartOf Nbbbca151795246b182b96b4ed53920b6
    40 Ndde3ae51cf8d462ea274d7410771d230
    41 sg:journal.1024626
    42 schema:keywords BackgroundIdiopathic nephrotic syndrome
    43 Clinical Trials Registry
    44 FRNS/
    45 INS
    46 Japan
    47 MMF treatment group
    48 MethodsWe
    49 RTX
    50 RTX therapy
    51 RTX treatment
    52 Recent studies
    53 SRNS patients
    54 Trials Registry
    55 UMIN Clinical Trials Registry
    56 additional treatment
    57 agents
    58 cases
    59 children
    60 chronic glomerular disease
    61 common chronic glomerular disease
    62 conjunction
    63 cyclophosphamide
    64 cyclosporine
    65 data
    66 days
    67 dependence
    68 development
    69 disease
    70 dose
    71 drugs
    72 duration
    73 duration of remission
    74 effect
    75 efficacy
    76 efficacy of MMF
    77 endpoint
    78 failure
    79 former group
    80 frequent relapses
    81 future
    82 glomerular disease
    83 group
    84 immunosuppressive agents
    85 immunosuppressive drugs
    86 important data
    87 issues
    88 limitations
    89 long-term use
    90 m2/day
    91 maintenance therapy
    92 mizoribine
    93 mofetil
    94 months
    95 multicenter
    96 mycophenolate mofetil
    97 nephrotic syndrome
    98 novel treatments
    99 open issues
    100 patients
    101 placebo treatment groups
    102 placebo-controlled trial
    103 primary endpoint
    104 recurrence
    105 registry
    106 relapse
    107 remainder
    108 remission
    109 results
    110 rituximab treatment
    111 safety
    112 safety of MMF
    113 side effects
    114 steroid dependence
    115 steroid therapy
    116 steroid-dependent nephrotic syndrome
    117 steroid-resistant nephrotic syndrome
    118 steroid-sensitive nephrotic syndrome
    119 study
    120 syndrome
    121 therapy
    122 time
    123 treatment
    124 treatment failure
    125 treatment groups
    126 trials
    127 use
    128 use of MMF
    129 schema:name Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07)
    130 schema:pagination 302
    131 schema:productId N8acd9564a58348b194d20647cb7d3ba2
    132 N9a8455c03b124bdd8c373c400cf23470
    133 Nc1a3f670f8584348ac21f3510c309aa7
    134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107953414
    135 https://doi.org/10.1186/s12882-018-1099-7
    136 schema:sdDatePublished 2022-05-10T10:21
    137 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    138 schema:sdPublisher Naf577b893bd1491293787045eb71cf87
    139 schema:url https://doi.org/10.1186/s12882-018-1099-7
    140 sgo:license sg:explorer/license/
    141 sgo:sdDataset articles
    142 rdf:type schema:ScholarlyArticle
    143 N07164c3a64e240d591f45ce38ff69715 rdf:first sg:person.016521443562.02
    144 rdf:rest Nf5ed053f79fe4b55a68947892065a037
    145 N07ae0c492d524c8098579f88d69aaeee rdf:first sg:person.01032464245.22
    146 rdf:rest N6997dbb1158b404bab86e7dece878201
    147 N0e556e5a77d0414997b9a79cb17ddca1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Drug Therapy, Combination
    149 rdf:type schema:DefinedTerm
    150 N1172bc6a41894d57acfa4f5244100082 rdf:first sg:person.01112735663.13
    151 rdf:rest Ndc6308bceb634f119dc2348948898e29
    152 N1764a0759997421d895569a119aa8908 rdf:first sg:person.013371647075.13
    153 rdf:rest N07ae0c492d524c8098579f88d69aaeee
    154 N290bf30513d64ac9bdeffc73ae445ac8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    155 schema:name Child
    156 rdf:type schema:DefinedTerm
    157 N3b371baeea78457f97868356d1be7b06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    158 schema:name Humans
    159 rdf:type schema:DefinedTerm
    160 N3c4efa40fd724349a18a3e4984c97ced schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    161 schema:name Recurrence
    162 rdf:type schema:DefinedTerm
    163 N54b1eee6ca2344019fb7bd3b6a21b430 rdf:first sg:person.01360637141.54
    164 rdf:rest rdf:nil
    165 N65461cf9e5e94ee09aee68ba2b8de9df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Mycophenolic Acid
    167 rdf:type schema:DefinedTerm
    168 N664795cad18e454686d95897912a2177 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Double-Blind Method
    170 rdf:type schema:DefinedTerm
    171 N6997dbb1158b404bab86e7dece878201 rdf:first sg:person.0611445101.47
    172 rdf:rest N1172bc6a41894d57acfa4f5244100082
    173 N6a45d6b1843b4cffad00a1fa21789906 rdf:first sg:person.0717317506.56
    174 rdf:rest N54b1eee6ca2344019fb7bd3b6a21b430
    175 N6f94ed8c33744652b5a4d48a265d351b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    176 schema:name Steroids
    177 rdf:type schema:DefinedTerm
    178 N79422b1e743742c5b263d5762ac9bbbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Immunologic Factors
    180 rdf:type schema:DefinedTerm
    181 N8acd9564a58348b194d20647cb7d3ba2 schema:name doi
    182 schema:value 10.1186/s12882-018-1099-7
    183 rdf:type schema:PropertyValue
    184 N92df3b3007a249fc9235a615c18ae6e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    185 schema:name Treatment Outcome
    186 rdf:type schema:DefinedTerm
    187 N9a8455c03b124bdd8c373c400cf23470 schema:name dimensions_id
    188 schema:value pub.1107953414
    189 rdf:type schema:PropertyValue
    190 N9c9711aba86e4e849a41f1730927606d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    191 schema:name Nephrotic Syndrome
    192 rdf:type schema:DefinedTerm
    193 Naf577b893bd1491293787045eb71cf87 schema:name Springer Nature - SN SciGraph project
    194 rdf:type schema:Organization
    195 Nbbbca151795246b182b96b4ed53920b6 schema:issueNumber 1
    196 rdf:type schema:PublicationIssue
    197 Nc1a3f670f8584348ac21f3510c309aa7 schema:name pubmed_id
    198 schema:value 30382824
    199 rdf:type schema:PropertyValue
    200 Ndc6308bceb634f119dc2348948898e29 rdf:first sg:person.012302533312.63
    201 rdf:rest N07164c3a64e240d591f45ce38ff69715
    202 Ndde3ae51cf8d462ea274d7410771d230 schema:volumeNumber 19
    203 rdf:type schema:PublicationVolume
    204 Nf5ed053f79fe4b55a68947892065a037 rdf:first sg:person.0755444204.45
    205 rdf:rest N6a45d6b1843b4cffad00a1fa21789906
    206 Nfecab5583147458d94a3a0b37cc07431 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    207 schema:name Rituximab
    208 rdf:type schema:DefinedTerm
    209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    210 schema:name Medical and Health Sciences
    211 rdf:type schema:DefinedTerm
    212 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    213 schema:name Clinical Sciences
    214 rdf:type schema:DefinedTerm
    215 sg:grant.7853213 http://pending.schema.org/fundedItem sg:pub.10.1186/s12882-018-1099-7
    216 rdf:type schema:MonetaryGrant
    217 sg:journal.1024626 schema:issn 1471-2369
    218 schema:name BMC Nephrology
    219 schema:publisher Springer Nature
    220 rdf:type schema:Periodical
    221 sg:person.01032464245.22 schema:affiliation grid-institutes:grid.63906.3a
    222 schema:familyName Sako
    223 schema:givenName Mayumi
    224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01032464245.22
    225 rdf:type schema:Person
    226 sg:person.01112735663.13 schema:affiliation grid-institutes:grid.63906.3a
    227 schema:familyName Ishikura
    228 schema:givenName Kenji
    229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01112735663.13
    230 rdf:type schema:Person
    231 sg:person.012302533312.63 schema:affiliation grid-institutes:grid.268441.d
    232 schema:familyName Ito
    233 schema:givenName Shuichi
    234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012302533312.63
    235 rdf:type schema:Person
    236 sg:person.013371647075.13 schema:affiliation grid-institutes:grid.31432.37
    237 schema:familyName Horinouchi
    238 schema:givenName Tomoko
    239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013371647075.13
    240 rdf:type schema:Person
    241 sg:person.01360637141.54 schema:affiliation grid-institutes:grid.31432.37
    242 schema:familyName Iijima
    243 schema:givenName Kazumoto
    244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01360637141.54
    245 rdf:type schema:Person
    246 sg:person.016521443562.02 schema:affiliation grid-institutes:grid.63906.3a
    247 schema:familyName Nakamura
    248 schema:givenName Hidefumi
    249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016521443562.02
    250 rdf:type schema:Person
    251 sg:person.0611445101.47 schema:affiliation grid-institutes:grid.267625.2
    252 schema:familyName Nakanishi
    253 schema:givenName Koichi
    254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611445101.47
    255 rdf:type schema:Person
    256 sg:person.0717317506.56 schema:affiliation grid-institutes:grid.31432.37
    257 schema:familyName Nozu
    258 schema:givenName Kandai
    259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717317506.56
    260 rdf:type schema:Person
    261 sg:person.0755444204.45 schema:affiliation grid-institutes:grid.265050.4
    262 schema:familyName Oba
    263 schema:givenName Mari Saito
    264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0755444204.45
    265 rdf:type schema:Person
    266 sg:pub.10.1007/s00467-003-1175-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010530284
    267 https://doi.org/10.1007/s00467-003-1175-4
    268 rdf:type schema:CreativeWork
    269 sg:pub.10.1007/s00467-003-1300-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032638307
    270 https://doi.org/10.1007/s00467-003-1300-4
    271 rdf:type schema:CreativeWork
    272 sg:pub.10.1007/s00467-004-1434-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1034927167
    273 https://doi.org/10.1007/s00467-004-1434-z
    274 rdf:type schema:CreativeWork
    275 sg:pub.10.1007/s00467-004-1778-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039990387
    276 https://doi.org/10.1007/s00467-004-1778-4
    277 rdf:type schema:CreativeWork
    278 sg:pub.10.1007/s00467-005-1877-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1025163770
    279 https://doi.org/10.1007/s00467-005-1877-x
    280 rdf:type schema:CreativeWork
    281 sg:pub.10.1007/s00467-006-0060-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039372955
    282 https://doi.org/10.1007/s00467-006-0060-3
    283 rdf:type schema:CreativeWork
    284 sg:pub.10.1007/s00467-006-0294-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001089825
    285 https://doi.org/10.1007/s00467-006-0294-0
    286 rdf:type schema:CreativeWork
    287 sg:pub.10.1007/s00467-007-0617-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004619628
    288 https://doi.org/10.1007/s00467-007-0617-9
    289 rdf:type schema:CreativeWork
    290 sg:pub.10.1007/s00467-008-0814-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047664910
    291 https://doi.org/10.1007/s00467-008-0814-1
    292 rdf:type schema:CreativeWork
    293 sg:pub.10.1007/s00467-009-1191-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052697168
    294 https://doi.org/10.1007/s00467-009-1191-0
    295 rdf:type schema:CreativeWork
    296 sg:pub.10.1007/s00467-009-1377-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022984402
    297 https://doi.org/10.1007/s00467-009-1377-5
    298 rdf:type schema:CreativeWork
    299 sg:pub.10.1007/s00467-011-1886-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1038755333
    300 https://doi.org/10.1007/s00467-011-1886-x
    301 rdf:type schema:CreativeWork
    302 sg:pub.10.1007/s00467-011-1894-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1032375811
    303 https://doi.org/10.1007/s00467-011-1894-x
    304 rdf:type schema:CreativeWork
    305 sg:pub.10.1007/s00467-012-2393-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020767792
    306 https://doi.org/10.1007/s00467-012-2393-4
    307 rdf:type schema:CreativeWork
    308 sg:pub.10.1007/s004670050558 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045165754
    309 https://doi.org/10.1007/s004670050558
    310 rdf:type schema:CreativeWork
    311 sg:pub.10.1007/s10157-014-1030-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1019458362
    312 https://doi.org/10.1007/s10157-014-1030-x
    313 rdf:type schema:CreativeWork
    314 sg:pub.10.1007/s10157-016-1313-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036768788
    315 https://doi.org/10.1007/s10157-016-1313-5
    316 rdf:type schema:CreativeWork
    317 sg:pub.10.1007/s10157-016-1319-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1022803771
    318 https://doi.org/10.1007/s10157-016-1319-z
    319 rdf:type schema:CreativeWork
    320 grid-institutes:grid.265050.4 schema:alternateName Department of Medical Statistics, Toho University, Tokyo, Japan
    321 schema:name Department of Medical Statistics, Toho University, Tokyo, Japan
    322 rdf:type schema:Organization
    323 grid-institutes:grid.267625.2 schema:alternateName Department of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
    324 schema:name Department of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
    325 rdf:type schema:Organization
    326 grid-institutes:grid.268441.d schema:alternateName Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
    327 schema:name Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan
    328 rdf:type schema:Organization
    329 grid-institutes:grid.31432.37 schema:alternateName Department of Pediatrics, Kobe University Graduate School of Medicine, 5-1 Kusunoki-cho 7 chome, Chuo-ku, 650-0017, Kobe, Japan
    330 schema:name Department of Pediatrics, Kobe University Graduate School of Medicine, 5-1 Kusunoki-cho 7 chome, Chuo-ku, 650-0017, Kobe, Japan
    331 rdf:type schema:Organization
    332 grid-institutes:grid.63906.3a schema:alternateName Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan
    333 Division for Clinical Trials, Department of Clinical Research Promotion, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan
    334 Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
    335 schema:name Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan
    336 Division for Clinical Trials, Department of Clinical Research Promotion, Clinical Research Center, National Center for Child Health and Development, Tokyo, Japan
    337 Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan
    338 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...